7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione for use in the treatment of borderline personality disorder
Patent Information
- Application Number
- PCT/EP2024/063349
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-21
Smart Images

Figure IMGF000006_0001 
Figure IMGF000011_0001 
Figure IMGF000012_0001
Abstract
Description
[0001] -(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7- DIHYDRO-1 H-PURINE-2, 6-DIONE FOR USE IN THE TREATMENT
[0002] OF BORDERLINE PERSONALITY DISORDER
[0003] FIELD OF THE INVENTION
[0004] The present invention relates to 7-(4-chlorobenzyl)-l-(3-hydroxypropyl)-3-methyl-8-(3- (trifluoromethoxy)-phenoxy)-3,7-dihydro-lH-purine-2, 6-dione (Compound 1) or a pharmaceutical composition comprising Compound 1 for the use in the prevention or treatment of Borderline Personality Disorder (BPD).
[0005] BACKGROUND OF THE INVENTION
[0006] BPD is a chronic mental disorder with an estimated prevalence of around 2% in the general population and is associated with a severe impairment of quality of life (Oldham et al., 2010). Patients with BPD often have psychiatric comorbidities (Axis I disorders as per DSM-IV); concomitant mood, anxiety, substance use, and eating disorders have been frequently reported (Shah et al., 2018). The main symptom clusters of BPD include affective instability, disturbed interpersonal relations, impulsive behavioural dyscontrol, and cognitive-perceptual symptoms. Affective symptoms and impulsivity have been considered core symptoms of BPD. Patients typically experience intense fears of real or imagined abandonment, which may result in inappropriate anger even when faced with a realistic short-term separation or when there are unavoidable changes in plans (Palihawadana et al., 2019). Even the presence of a single diagnostic feature of BPD is predictive for poor functioning and psychiatric illness burden (Ellison et al., 2016). Patients with BPD have high rates of deliberate self-harm and a rate of completed suicide that is 50 times that in the general population (Skodol et al., 2002).
[0007] The prevalence of BPD differs between the general population and clinical settings. The reported prevalence of BPD in clinical settings is approximately 10 to 12% for outpatient clinics and 20 to 22% for inpatient clinics. However, these estimates can vary due to the lack of standardization of assessment tools for diagnosis and regional differences (Ellison et al., 2018). Across the globe, BPD patients suffer from significant stigma related to the disorder. There is often a delay in diagnosis, a reluctance for healthcare professionals to make a diagnosis at all, and there can be a tendency to focus rather on comorbid psychiatric diagnoses that have evidence-based, reimbursable treatments. Healthcare professionals may have strong negative feelings towards patients with BPD and there can be a reluctance to share a diagnosis with patients or to offer treatments in some cases. Clinicians may also be reluctant to give the diagnosis of BPD to ensure that patients are more likely to be accepted into the larger mental health system for treatment and avoid marginalization(Aviram et al., 2006; Kealy and Ogrodniczuk, 2010). Collectively, these factors may contribute to higher rates of underdiagnosis or misdiagnosis of the disorder (Morgan and Zimmerman, 2015) and suboptimal quality of care and health outcomes for this population (Klein et al., 2022).
[0008] Treatment guidelines recommend psychotherapy as the mainstay of treatment for BPD (Oldham et al., 2010). Specialized psychotherapies for BPD, however, are difficult to access, expensive to deliver, and require substantial time and resource commitments from patients. Evidence based psychotherapies for BPD include dialectical behavioural therapy (DBT), mentalization-based therapy (MBT), transference-focused psychotherapy (TFP), and Schema-Based Therapy (SBT). DBT is the best studied and arguably the most widely used of the four therapies but has several disadvantages. DBT in clinical practice is costly, time intensive, and requires specialised clinical providers, making access for all patients in need of therapy difficult (Paris et al., 2015). While generalist models of care have shown potential, not all patients respond to them and patients with greater personality dysfunction still require intensive specialist treatment (Choi-Kain et al., 2017). Despite some advances in the therapy of BPD, a sizeable portion of patients (about 40%) never achieve recovery from the disorder. In addition to their severely impacted quality of life, those patients have a poor prognosis for other important outcomes, such as vocational impairment, disability, physical morbidity, and mortality (Temes et al., 2018).
[0009] There are no approved medications for BPD. Despite the absence of approved pharmacotherapy, medication is commonly used not only to treat comorbid psychiatric disorders, but also as off-label adjunctive treatment to target symptoms of BPD themselves. This includes treatment of affective dysregulation symptoms such as depressive symptoms (with SSRI or related drugs), impulsive- behavioural dyscontrol symptoms such as impulsivity, aggression, self-destructive behaviour (with SSRIs, low-dose atypical antipsychotics, and mood stabilizers (Lieb et al., 2010)), and cognitive perceptual symptoms such as paranoid thinking (with low-dose antipsychotics, (Oldham et al., 2010). However, no drug is approved for the treatment of BPD, and no standard-of-care pharmacological treatment of the disease exists. A great unmet medical need remains for agents improving core characteristics of BPD.
[0010] It thus is an object of the present invention to provide a compound being effective in the prevention or treatment of BPD.
[0011] 7-(4-chlorobenzyl)-l-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-lH- purine-2, 6-dione is a potent and selective inhibitor of the transient receptor potential (TRP) cation channel subfamily C, member 5 (TRPC5) and was first described in WO°2014 / 143799 (Example 7a, p.441; Example 356, p. 612). TRPC5 inhibitors modulate the function of TRPC5 by inhibiting a TRPC5- mediated ion flux or by inhibiting the inward current, the outward current, or both currents mediated by TRPC5. Based on their TRPC5-inhibiting activity they are described in WO2014 / 143799 for being potentially useful in treating conditions including neuropsychiatric disorders, a neurodegenerative disorders, nephropathy, and seizure disorders.
[0012] SUMMARY OF THE INVENTION
[0013] It was found that 7-(4-chlorobenzyl)-l-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)- 3, 7-dihydro-lH-purine-2, 6-dione is a promising new therapeutic agent for preventing or treating BPD.
[0014] Accordingly, the following items are provided in accordance with the present invention:
[0015] [1] 7-(4-chlorobenzyl)-l-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7- dihydro-lH-purine-2, 6-dione (Compound 1) for use in the prevention or treatment of Borderline Personality Disorder (BPD).
[0016] [2] Pharmaceutical composition comprising Compound 1 for use in the prevention or treatment of BPD.
[0017] [3] Compound 1 or pharmaceutical composition comprising Compound 1 for use according to [1] or [2], wherein the prevention or treatment of BPD is in adults.
[0018] [4] Compound 1 or pharmaceutical composition comprising Compound 1 for use according to any of [1] to [3], wherein the use is in the treatment of BPD.
[0019] [5] Compound 1 or pharmaceutical composition comprising Compound 1 for use according to any of [1] to [4], wherein Compound 1 is administered in an amount of 50 mg to 150 mg, preferably in amount of 75 mg to 125 mg, and more preferably in an amount of 75 or 125 mg per day.
[0020] [6] Compound 1 or pharmaceutical composition comprising Compound 1 for use according to any of [1] to [5], wherein the patient suffering from BPD exhibits at the beginning of the treatment a Zanarini Borderline Personality Disorder (ZAN-BPD) score of > 9, with a question #2 Affective Instability score of >2.
[0021] [7] Compound 1 or pharmaceutical composition comprising Compound 1 for use according to any of [1] to [6], wherein the treatment does not increase the incidence of suicidal ideation or non-suicidal self-injury as measured by the Columbia Suicide Severity Rating Scale (C- SSRS).
[0022] DETAILED DESCRIPTION OF THE INVENTION
[0023] The present invention is based on the results of a phase II clinical trial investigating the safety and efficacy of Compound 1 in the treatment of BPD. Treatment efficacy was assessed based on the change from baseline in core signs and symptoms of BPD as measured by the Zanarini Borderline Personality Disorder (ZAN-BPD) Rating Scale after 10 weeks of treatment.
[0024] The results of the phase II clinical trial show that, on average, all trial participants show a marked reduction in ZAN-BPD total score over the 12 weeks of treatment. The mean ZAN-BPD score decreases from a baseline of 16.2 + / - 5.1 (scores between 10-18 are considered moderate, and scores between 19-27 are considered serious) to an average of 7.2 + / - 5.5 at the end of the study (scores of 0-9 are considered mild). Compound 1 was well-tolerated and was not associated with an increased risk for suicidal thinking or non-suicidal self-injury in patients with BPD.
[0025] In the first aspect, the present invention thus relates to Compound 1 or a pharmaceutical composition comprising Compound 1 for use in the prevention or treatment of BPD.
[0026] In a preferred embodiment, the present invention relates to Compound 1 or a pharmaceutical composition comprising Compound 1 for use in the prevention or treatment of BPD in adults.
[0027] In addition, the present invention relates to Compound 1 or a pharmaceutical composition comprising Compound 1 for use in the prevention or treatment of
[0028] • difficulties in regulating emotions,
[0029] • anxiety symptoms,
[0030] • depression symptoms, and / or
[0031] • overall disease severity in adult patients suffering from BPD.
[0032] Treatment efficacy in difficulties in regulating emotions can be determined based on the change from baseline as measured by the Difficulties in Emotion Regulation Scale (DERS-16) after 10 weeks of treatment.
[0033] Treatment efficacy in anxiety symptoms can be determined based on the change from baseline as measured by the State-Trait Anxiety Inventory (STAI-S) after 10 weeks of treatment.
[0034] Treatment efficacy in depression symptoms can be determined based on the change from baseline as measured by the Patient Health Questionnaire (PHQ-9) after 10 weeks of treatment.
[0035] Treatment efficacy in overall disease severity can be determined based on the change from baseline as measured by the Clinical Global Impression Severity scale (CGI-S) after 10 weeks of treatment or the Patient Global Impression Severity scale (PGI-S) after 10 weeks of treatment. In the phase II clinical trial, the use of Compound 1 in the treatment of BPD does not increase the incidence of suicidal ideation or non-suicidal self-injury as measured by the Columbia Suicide Severity Rating Scale (C-SSRS).
[0036] The term "Compound 1" as employed herein comprises the anhydrate as well as hydrates and solvates of Compound 1 in amorphous or crystalline form, respectively.
[0037] Compound 1 can be prepared as described previously in EP22214917.1 by the following process:
[0038] In the pharmaceutical composition comprising Compound 1, Compound 1 is combined with one or more pharmaceutically acceptable excipients or carriers. It can take any form suitable for administering Compound 1 including solid, semi-solid, and liquid dosage forms such as, for example, tablets, dragees, capsules, pills, granules, emulsions, microemulsions, solutions, suspensions, syrups, elixirs, ointments, pastes, creams, gels, lotions, patches, injectables, and inhalants, e.g., in form of powders and sprays.
[0039] The pharmaceutical composition can be administered topically, orally, transdermally, rectally, parentally, intranasally, intravenously, subcutaneously, sublingually or by inhalation.
[0040] In a particular preferred embodiment, the pharmaceutical composition is a tablet for oral administration as described previously in EP23155058.3 comprising Compound 1, a sugar alcohol, and optionally one or more further pharmaceutically acceptable excipient(s) selected from binders, fillers, disintegrants, glidants, lubricants, wetting agents, surfactants and preservatives.
[0041] In an exemplary embodiment, the pharmaceutical composition is a tablet and comprises
[0042] 5-50 % [w / w] Compound 1 (incorporated in form of micronized or nanosized particles),
[0043] 40-80 % [w / w] sugar alcohol,
[0044] 0-10 % [w / w] binder,
[0045] 0-30 % [w / w] filler,
[0046] 0-10 % [w / w] disintegrant, 0-5 % [w / w] glidant,
[0047] 0-5 % [w / w] lubricant, and 0-1 % [w / w] each of a wetting agent, a surfactant and a preservative, wherein the amount of Compound 1 and the respective excipients adds up to a total of 100 % [w / w].
[0048] In a further preferred embodiment, the pharmaceutical composition is a tablet, which is coated.
[0049] A corresponding coating composition preferably comprises one or more film-forming polymer(s) and one or more pharmaceutically acceptable excipient(s).
[0050] In a preferred embodiment, the pharmaceutical composition is prepared by a wet granulation method.
[0051] In a particularly preferred embodiment, the pharmaceutical composition is prepared by a fluid bed granulation method, wherein Compound 1 is suspended in the granulation liquid.
[0052] The dose of Compound 1 in adults is 50 mg to 150 mg per day, preferably 75mg to 125mg per day, more specifically 75 mg or 125 mg per day.
[0053] In a preferred embodiment, the dose of Compound 1 in adults 75 mg or 125 mg per day.
[0054] In a preferred embodiment, Compound 1 is administered orally in a single dose once per day, either in fasted or fed state, more preferably in the fed state. In an alternative embodiment, Compound 1 is administered orally in several divided doses per day, for example twice or three times a day.
[0055] The dose may be adapted depending on the severity of the symptom(s), age, gender, weight, and type of dosage form.
[0056] In another embodiment, Compound 1 is administered in combination with another psychotropic medication (for example, an antipsychotic drug, an antidepressant drug, or a mood stabilizer drug).
[0057] In another aspect, the present invention relates to a method of prevention or treatment of BPD in adults, including the administration of Compound 1 or a pharmaceutical composition comprising Compound 1 as described in the foregoing to a patient in need thereof.
[0058] EXAMPLES
[0059] Example 1 - Preparation of Compound 1
[0060] List of abbreviations:
[0061] APCI Atmospheric Pressure Chemical Ionization abs. absolute aq. aqueous
[0062] BHT 3,5-di-tert-butyl-4-hydroxytoluol cone concentrated
[0063] DCM dichloromethane
[0064] DIPEA / V-ethyl-diisopropylamine
[0065] DMAc dimethylacetamide
[0066] DMF dimethylformamide
[0067] DMSO dimethylsulfoxide equiv. equivalents
[0068] ESI Electrospray Ionization
[0069] EtOAc ethyl acetate g gram h hour(s)
[0070] HOAc acetic acid
[0071] HPLC high performance liquid chromatography iPr iso-propyl kg kilogram
[0072] NMP / V-methyl-2-pyrrolidon
[0073] NMR Nuclear Magnetic Resonance
[0074] MeCN acetonitrile
[0075] MeOH methanol min minute(s) mg milligram mL milliliter
[0076] M Molar (mol / L)
[0077] TBABr tetra-n-butylammonium bromide
[0078] THF tetrahydrofuran
[0079] NMR method
[0080] NMR spectra were recorded on a Bruker AVANCE III instrument with a frequency of 600 MHz for1H- NMR experiments and 150 MHz for13C-NMR experiments, respectively, and using TopSpin 3.2 pl6 software for analysis. Chemical shifts are given in parts per million (ppm) downfield from internal reference trimethylsilane in 6 units. Selected data are reported in the following manner: chemical shift (multiplicity, coupling constants (J), number of hydrogens). Abbreviations are as follows: s (singulet), d (doublet), t (triplet), q (quartet), spt (septet), m (multiplet), br (broad).
[0081] X-ray powder diffraction (XRPD) diagram X-ray powder diffraction measurements were performed using a Bruker D8 Advance-diffractometer in reflection mode fitted with a LynxEye Position Sensitive detector, and a Cu-anode as X-ray source with CuKal radiation (X = 1.54060 A, 40kV, 40mA). The standard error range for the 2-theta values is ±0.2°.
[0082] Step 1: Preparation of 8-bromo-7-(4-chlorobenzyl)-3-methyl-3,7-dihydro-lH-purine-2, 6-dione (Compound 2)
[0083] 8-Bromo-3-methylxanthine (20.0 g, 81.6 mmol, 1.0 equiv.) and BHT (0.8 g, 3.6 mmol, 0.04 equiv.) are dissolved in dimethylacetamide (210 mL). The mixture is heated up to 85 °C. A solution of 4- chlorobenzyl chloride (15.8 g, 97.9 mmol, 1.2 equiv.) in dimethylacetamide (20 mL) is added and rinsed with dimethylacetamide (10 mL). Diisopropylethylamine (11.1 g, 85.7 mmol, 1.05 equiv.) is added and rinsed with dimethylacetamide (10 mL). The reaction is stirred at 85 °C until the starting material is consumed (8-bromo-3-methylxanthine < 0.3 %). Optionally, further dosage of diisopropylethylamine (0.5 g, 4.1 mmol, 0.05 equiv.) may be performed to complete the reaction. After complete conversion, hydrochloric acid (4M, 0.8 g, 8.2 mmol, 0.1 equiv.) is added. The reaction solvent is removed partially via vacuum distillation (until a remaining volume of approx. 150 mL of the reaction mixture). Acetonitrile (150 mL) is added, and the product suspension is slowly cooled to 20 °C. The product is isolated via filtration and the filter cake is washed two times with acetonitrile (50 mL). The isolated material is dried under reduced pressure at 50 °C giving Compound 2 (28.7 g, 78.0 mmol, 95 % yield, 99.9 % purity) as a colorless solid. Melting point: 270-271 °C.
[0084] 3H NMR (DMSO-dg) 6: 11.37 (s, 1H), 7.44 (d, J=8.5 Hz, 2H), 7.29 (d, J=8.5 Hz, 2H), 5.48 (s, 2H), 3.34 (s, 3H);13C NMR (DMSO-d6) 6: 154.0, 150.5, 149.3, 134.5, 132.6, 129.0, 128.7, 127.9, 108.6, 48.6, 28.5; HRMS (ESI): m / z 369, ([M+H]+, exp. 368.9763, calc. 368.9748).
[0085] Step 2: Preparation of8-bromo-7-(4-chlorobenzyl)-l-(3-hydroxypropyl)-3-methyl-3,7-dihydro-lH- purine-2, 6-dione (Compound 3)
[0086] Compound 2 (20.0 g, 54.1 mmol, 1.0 equiv.) and sodium bicarbonate (6.8 g, 81.2 mmol, 1.5 equiv.), tetrabutylammonium bromide (0.8 g, 2.7 mmol, 0.05 equiv.) are suspended in dimethylacetamide (170 mL). The mixture is heated to 110 °C. 3-chloro-l-propanol (7.7 g, 81.5 mmol, 1.5 equiv.) is added, and rinsed with dimethylacetamide (10 mL). Vacuum (200-400 mbar) is then applied. The reaction is stirred at 110 °C until the starting material is consumed (Compound 2 < 0.5 %). After complete conversion, the reaction mixture is cooled to 80 °C, filtered and rinsed with dimethylacetamide (30 mL). Water (160 mL) is added to the filtrate at 90 °C, then sodium bicarbonate (0.5 g, 5.4 mmol, 0.1 equiv.) is added. The mixture is cooled to 70 °C and seed crystals (47 mg) are added. The crystal suspension is cooled to 40 °C over 60 min, heated to 70 °C, kept for at least 15 min at 70°C and cooled to 20 °C over 150 min and stirred for 1 h. The product is isolated via filtration and the filter cake is washed with water (160 mL). The isolated material is dried under reduced pressure at 60 °C giving Compound 3 (16.1 g, 37.7 mmol, 91 % yield, 98.7 % purity) as a colorless solid. Melting point: 148-149 °C.
[0087] 3H NMR (DMSO-dg) 6: 7.43 (d, J=8.5 Hz, 2H), 7.30 (d, J=8.5 Hz, 2H), 5.52 (s, 2H), 4.48 (t, J=5.2 Hz, 1H), 3.89-3.96 (m, 2H), 3.43-3.48 (m, 2H), 3.38 (s, 2H), 1.65-1.74 (m, 2H);13C NMR (DMSO-d6) 6: 153.5, 150.3, 147.9, 134.5, 132.6, 129.0, 128.7, 128.2, 108.2, 58.7, 48.7, 38.5, 30.8, 29.5; HRMS (ESI): m / z 427, ([M+H]+, exp. 427.0188, calc. 427.0167).
[0088] Step 3: Preparation of 7-(4-chlorobenzyl)-l-(3-hydroxypropyl)-3-methyl-8-(3- (trifluoromethoxy)phenoxy)-3,7-dihydro-lH-purine-2, 6-dione (Compound 1) [crude] Compound 3 (20.0 g, 46.8 mmol, 1.0 equiv.), tetrabutylammonium bromide (0.8 g, 2.4 mmol, 0.05 equiv.) and sodium carbonate (3.5 g, 32.7 mmol, 0.7 equiv.) are suspended in N-methyl-2- pyrrolidone (135 mL). The mixture is heated to 50 °C. 3-(Trifluoromethoxy)phenol (9.2 g, 51.7 mmol, 1.1 equiv.) is added and rinsed with / V-methyl-2-pyrrolidone (10 mL). The mixture is heated to 120 °C and stirred at 120 °C under reduced pressure (200-400 mbar) until the starting material is consumed (Compound 3 < 1.0 %). After complete conversion, the reaction mixture is cooled to 80°C, filtered and rinsed with N-methyl-2-pyrrolidone (15 mL). Acetonitrile (40 mL) is added. Water (110 mL) is added in at least 30 min. The mixture is cooled to 58 °C and seed crystals (20 mg) are added. The crystal suspension is consecutively cooled to 40 °C, heated to 60 °C, kept for at least 15 min at same temperature and cooled to 20 °C. The product is isolated via filtration and the filter cake is washed with water (160 mL) and n-heptane (40 mL). The isolated material is dried under reduced pressure at 60 °C giving Compound 1 [crude] (22.1 g, 42.1 mmol, 90 % yield, 98.5 % purity) as a colorless solid. Melting point: 124-125 °C.
[0089] 3H NMR (DMSO-dg) 6: 7.56-7.63 (m, 1H), 7.49 (s, 1H), 7.40-7.45 (m, 5H), 7.32 (br d, J=8.3 Hz, 1H), 5.44 (s, 2H), 4.47 (t, J=5.3 Hz, 1H), 3.87-3.96 (m, 2H), 3.39-3.48 (m, 2H), 3.29 (s, 3H), 1.63-1.75 (m, 2H);13C NMR (DMSO-dg) 6: 153.8, 153.7, 152.1, 150.5, 148.6, 145.4, 135.1, 132.5, 131.3, 129.5, 128.7, 118.8, 118.2, 119.9, 113.1, 102.5, 58.7, 45.8, 38.3, 30.9, 29.5; HRMS (ESI): m / z 525 ([M+H]+, exp. 525.1151, calc. 525.1147).
[0090] Step 4: Recrystallization of 7-(4-chlorobenzyl)-l-(3-hydroxypropyl)-3-methyl-8-(3- ( trifluoromethoxy)phenoxy)-3, 7-dihydro-lH-purine-2, 6-dione ( Compound 1 ) Compound 1 [crude] (20.0 g, 38.1 mmol, 1.0 equiv.) is suspended in ethyl acetate (90 mL). The mixture is heated to 65 °C, filtered, and n-heptane (100 mL) is added to the solution. The mixture is cooled to 53 °C and seed crystals (40 mg) are introduced. The crystalline suspension is stirred at least 60 min before n-heptane (100 mL) is being added and stirred another 60 min at 53 °C. The suspension is cooled to 5 °C over 90 min, and stirred 120 min at 5 °C. The product is isolated via filtration and the filter cake is washed with n-heptane (100 mL). The isolated material is dried under reduced pressure at 50 °C giving Compound 1 (18.9 g, 36.2 mmol, 95 % yield, 99.8 % purity) as a colorless solid. Melting point: 124 °C.
[0091] 3H NMR (DMSO-dg) 6: 7.56-7.63 (m, 1H), 7.49 (s, 1H), 7.40-7.45 (m, 5H), 7.32 (br d, J=8.3 Hz, 1H), 5.44 (s, 2H), 4.47 (t, J=5.3 Hz, 1H), 3.87-3.96 (m, 2H), 3.39-3.48 (m, 2H), 3.29 (s, 3H), 1.63-1.75 (m, 2H);13C NMR (DMSO-dg) 6: 153.8, 153.7, 152.1, 150.5, 148.6, 145.4, 135.1, 132.5, 131.3, 129.5, 128.7, 118.8, 118.2, 119.9, 113.1, 102.5, 58.7, 45.8, 38.3, 30.9, 29.5; HRMS (ESI): m / z 525 ([M+H]+, exp. 525.1150, calc. 525.1147).
[0092] The recrystallized Compound 1 prepared according to Step 4 was analyzed by X-ray powder diffraction. Results as shown in Table 1.
[0093] Table 1 XRPD data for Compound 1
[0094] Example 2 - Pharmaceutical composition
[0095] Compound 1-containing immediate release film-coated tablet formulations were prepared in dose strengths of 5 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 125 mg.
[0096] Tablets were prepared by wet-granulation using mannitol and microcrystalline cellulose as filler, magnesium stearate as lubricant, hydroxypropylcellulose as binder, and croscarmellose sodium as disintegrant, while Compound 1 was suspended in the granulation liquid.
[0097] Two tablet formulations were prepared, formulation A and formulation B: Table 2 Composition formulation A
[0098] *Composition film coat: Hypromellose 2910, Macrogol 6000, titanium dioxide, talc, iron oxide red
[0099] Table 3 Composition formulation B
[0100] “Composition film coat: Hypromellose 2910, hydroxypropylcellulose, calcium carbonate, isomalt, medium chain triglycerides, iron oxide yellow
[0101] The 100 mg tablets of formulation A were dull red, oval, biconvex, film-coated tablets about 15 x 7 mm in length and width.
[0102] The tablets of formulation B had the following size, shape, and color:
[0103] The wet-granulation process used for preparing the tablets of formulations A and B was a fluid bed granulation process using the following granulation conditions:
[0104] Batch size 45 kg final blend:
[0105] Batch size 100 kg final blend:
[0106] The respective wet-granulation processes can be summarized as follows.
[0107] Formulation A
[0108] MANUFACTURE OF Compound 1 GRANULATION LIQUID (STEP 1)
[0109] Step 1.1 Preparation of the granulation suspension
[0110] Hydroxypropylcellulose, sodium laurilsulfate and mannitol (optionally pre-screened) are dissolved in purified water. Afterwards jet-milled Compound 1, D90 < 15 pm, is suspended therein to obtain a granulation liquid.
[0111] MANUFACTURE OF Compound 1 GRANULES (STEP 2)
[0112] Step 2.1 and Step 2.2 Pre-heating and granulating
[0113] Mannitol is pre-screened and pre-heated and then granulated with the granulation liquid obtained in Step 1 in a suitable fluid-bed granulator.
[0114] Step 2.3 Drying
[0115] The obtained wet granules are dried in the fluid-bed granulator to obtain granules, dried.
[0116] Step 2.4 Dry screening
[0117] The dried granules are screened with a suitable screen.
[0118] MANUFACTURE OF Compound 1 FINAL BLEND (STEP 3)
[0119] Step 3.1 Main blending
[0120] Microcrystalline cellulose, croscarmellose sodium and the pre-screened granules obtained in Step 2 are blended to obtain a main blend.
[0121] Step 3.2 Pre-screening
[0122] A part of the main blend is pre-screened with magnesium stearate.
[0123] Step 3.3 Final blending
[0124] The remainder of main blend and the pre-screened material are blended to produce a final blend.
[0125] MANUFACTURE OF Compound 1 TABLET CORES (STEP 4)
[0126] Step 4.1 Tablet compression
[0127] The final blend obtained in Step 3 is compressed into tablet cores using a suitable tablet press.
[0128] MANUFACTURE OF Compound 1 FILM-COATED TABLETS (STEP 5)
[0129] Step 5.1 Preparation of the film-coating suspension
[0130] The film-coating mixture (Opadry® red) is dispersed in purified water by stirring in a suitable mixing vessel to prepare a film-coating suspension. Step 5.2 Film coating
[0131] The tablet cores obtained in Step 4 are coated with the film-coating suspension by spraying in a drum coater to produce Compound 1 film-coated tablets.
[0132] Formulation B
[0133] MANUFACTURE OF Compound 1 GRANULATION LIQUID (STEP 1)
[0134] Step 1.0 Preparation of the granulation suspension
[0135] Hydroxypropylcellulose, sodium laurilsulfate and mannitol are dissolved in purified water. Afterwards jet-milled Compound 1, D90 < 15 pm, is suspended therein to obtain a granulation liquid.
[0136] MANUFACTURE OF Compound 1 GRANULES (STEP 2)
[0137] Step 2.1 and Step 2.2 Pre-heating and granulating
[0138] Mannitol is pre-screened and pre-heated and then granulated with the granulation liquid obtained in Step 1 in a suitable fluid-bed granulator.
[0139] Step 2.3 Drying
[0140] The obtained wet granules are dried in the fluid-bed granulator to obtain granules, dried.
[0141] MANUFACTURE OF Compound 1 FINAL BLEND (STEP 3)
[0142] Step 3.1 and Step 3.2 Main blending
[0143] Microcrystalline cellulose, croscarmellose sodium and the dried granules obtained in Step 2 are blended, and then magnesium stearate is added to obtain a main blend.
[0144] Step 3.3 and Step 3.4 Screening and final blending
[0145] The main blend is screened and finally blended to produce a final blend.
[0146] MANUFACTURE OF Compound 1 TABLET CORES (STEP 4)
[0147] Step 4.1 Tablet compression
[0148] The final blend obtained in Step 3 is compressed into tablet cores using a suitable tablet press.
[0149] MANUFACTURE OF Compound 1 FILM-COATED TABLETS (STEP 5)
[0150] Step 5.1 Preparation of the film-coating suspension
[0151] The film-coating mixture (Aquapolish® P) is dispersed in purified water by stirring in a suitable mixing vessel to prepare a film-coating suspension.
[0152] Step 5.2 Film coating
[0153] The tablet cores obtained in Step 4 are coated with the film-coating suspension by spraying in a drum coater to produce Compound 1 film-coated tablets.
[0154] Example 3 - Clinical trial
[0155] A phase II clinical trial was conducted for investigating the safety and efficacy of Compound 1 in the treatment of BPD. The purpose of the study was to find out whether Compound 1 helps to reduce symptoms in people with BPD and whether it is well tolerated. Four different doses of Compound 1 were tested in the study. This study was open to adults with BPD.
[0156] Participants were put into 5 groups by chance. Participants in 4 of the 5 groups took different doses of Compound 1. Participants in the fifth group took placebo. Participants took Compound 1 and placebo as tablets once a day. Placebo tablets looked like Compound 1 tablets but do not contain any drug.
[0157] After a screening period, participants were randomized to treatment for a duration of 12 weeks. The treatment period was followed by a 4-week follow-up period. During this time, they visited the study site about 12 times and got about 6 phone calls. At the visits, doctors asked participants about their symptoms. The results between the Compound 1 groups and the placebo group were then compared. The doctors also regularly checked the general health of the participants.
[0158] Study particulars were as follows.
[0159] Study design
[0160] The study objectives were to demonstrate a non-flat dose response curve for Compound 1, to evaluate the relationship between the dose of Compound 1 and improvement of the core signs and symptoms of BPD, as measured by the Zanarini Borderline Personality Disorder (ZAN-BPD) Rating Scale, to assess the treatment effect size of Compound 1 versus placebo, and to assess the safety profile of Compound 1. The study also assessed the change in other key psychiatric symptoms, including emotion dysregulation, anxiety, and depression in patients with BPD. Patients were permitted to continue psychotherapy if they were already receiving it at screening, but patients were not permitted to take any psychotropic medication.
[0161] The study was a multinational, multicentre, randomised, double-blind, placebo-controlled, parallel group trial.
[0162] Study medication
[0163] Compound 1 in an amount of 5, 25, 75 or 125 mg and matching placebo were supplied as film-coated tablets of formulation A of above Example 2.
[0164] Study population
[0165] In total, 390 patients with BPD with or without psychotherapy as described in Table 4 below were randomized into the trial. Table 4 Study population
[0166] Inclusion criteria
[0167] Patients with established diagnoses of BPD per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), as confirmed by Structured Interview for DSM-5 Personality Disorder (SCID-5-PD) at screening, with the following clinical features:
[0168] 1. ZAN-BPD of > 9 at screening (Visit 1) and randomization (Visit 2), with question #2 Affective Instability score of >2.
[0169] 2. Male or female patients, 18-65 years of age at the time of consent.
[0170] 3. Women of childbearing potential (WOCBP) able and willing to use two methods of contraception, as confirmed by the Investigator, which include one highly effective method of birth control per ICH M3 (R2) that results in a low failure rate of less than 1%, plus one barrier method.
[0171] 4. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
[0172] Exclusion criteria
[0173] 1. Current diagnosis of paranoid, schizoid, schizotypal and antisocial personality disorders, as confirmed by SCID-5-PD at screening visit.
[0174] 2. Lifetime diagnosis for schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar I disorder, or delusional disorder as confirmed by the SCID-5 at the screening visit.
[0175] 3. Any other mental disorder (in addition to those described in Exclusion criteria 1 and 2) that is the primary focus of treatment in the last 6 months prior to randomization, as per the clinical judgement of the investigator. Inpatient stay or hospitalization due to worsening of BPD within 3 months prior to randomization. Initiation or change in any type or frequency of psychotherapy (e.g., DBT, cognitive behavior therapy (CBT), Interpersonal therapy) for BPD within 3 months prior to screening; patients with ongoing, stable psychotherapy >3 months prior to screening (and intend to maintain the same frequency during the study) may qualify as per clinical judgement of the investigator. Any ongoing use of psychotropic medications within 7 days prior to randomization or during the course of study (unless allowed per protocol; concomitant use of benzodiazepines and non-benzodiazepine hypnotics were allowed for up to 7 days at a dose equivalent to < 1.0 mg of lorazepam per day, for the management of AEs (e.g., anxiety and / or insomnia));
[0176] Investigators may use their clinical discretion to wash out (at least 3 half-lives of referenced medication) psychotropic medications during screening period, while such wash-out of ongoing psychotropic medication must be complete at least 7 days prior to randomization. Any suicidal behavior in the past 1 year (i.e., actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior) prior to screening and during the screening period. Any suicidal ideation of type 4 or 5 in the Columbia Suicidal Severity Rating Scale (C-SSRS) in the past 3 months (i.e., active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent) prior to screening and during the screening period. Any non-suicidal self-injury that leads to hospitalization within 3 months prior to randomization. Diagnosis of moderate or severe substance use disorder within the last 3 months of screening visit (as defined in DSM-5-substance use disorder) or at randomization visit; in case of a positive drug screen, patient may be considered for inclusion in the study, at the discretion of the investigator, if patient does not have moderate or severe substance use disorder as per DSM-5. Use of alternative or traditional medicine (e.g., Chinese traditional medicine, herbal medication, St. John's Wort, etc.) at the time of randomization and / or planned use during the course of the study. Patients who must or wish to continue the intake of restricted medications (as specified in the protocol) or any drug considered likely to interfere with the safe conduct of the trial. Known history of HIV infection or positive result for active, ongoing Hepatitis B or C infection. 14. History of seizure disorders, stroke, brain tumor or any other major neurological or developmental illness
[0177] 15. Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to randomization or planned elective surgery requiring general anesthesia or hospitalization for more than 1 day during the study period, e.g., hip replacement.
[0178] 16. Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.
[0179] 17. Patients not expected to comply with the protocol requirements or not expected to complete the trial as scheduled (that, in the investigator's opinion, makes the patient an unreliable trial participant).
[0180] 18. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
[0181] 19. Clinically significant finding of the physical examination, vital signs (including blood pressure (BP) and pulse rate (PR)), ECG or laboratory value that would jeopardize the patient's safety while participating in the trial or their capability to participate in the trial.
[0182] 20. Symptomatic / unstable / uncontrolled or clinically relevant concomitant disease (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.) or any other clinical condition that would jeopardize the patient's safety while participating in the trial or capability to participate in the trial.
[0183] 21. Use of any investigational procedure within 30 days prior to randomization; in case of exposure to an investigational medicinal product, investigator must ensure that it is adequately washed out prior to randomization (at least 30 days or 5 half-lives of the investigational medicinal product, whatever is longer).
[0184] 22. Patients with an allergy to Compound 1 and / or any of the excipients of the study medication; a list of the Compound 1- and placebo-containing formulation ingredients will be provided in the ISF.
[0185] Randomization
[0186] Patients eligible for the trial based on the afore-mentioned criteria were assigned at random in a 2.5:1:1:1:2 ratio to one of the 5 study arms (placebo, 5 mg, 25 mg, 75 mg, and 125 mg once per day each) and followed for 12 weeks of treatment. Variables assessed
[0187] The results of the primary efficacy endpoint and a key safety endpoint are summarized below.
[0188] Efficacy Endpoints
[0189] The primary endpoint in this trial was the change from baseline in core signs and symptoms of BPD as measured by the Zanarini Borderline Personality Disorder Rating Scale (ZAN-BPD) after 10 weeks of treatment.
[0190] The secondary efficacy endpoints were:
[0191] • The number of patients achieving treatment response after 10 weeks of treatment (response defined as >30% reduction of the ZAN-BPD total score).
[0192] • The change from baseline in difficulties in regulating emotions as measured by the Difficulties in Emotion Regulation Scale (DERS-16) after 10 weeks of treatment.
[0193] • The change from baseline in anxiety symptoms as measured by the State-Trait Anxiety Inventory (STAI-S) after 10 weeks of treatment.
[0194] • The change from baseline in depression symptoms as measured by the Patient Health Questionnaire (PHQ-9) after 10 weeks of treatment.
[0195] • The change from baseline in overall disease severity as measured by the Clinical Global Impression Severity scale (CGI-S) after 10 weeks of treatment.
[0196] • The change from baseline in overall disease severity as measured by the Patient Global Impression Severity scale (PGI-S) after 10 weeks of treatment.
[0197] Safety Endpoints
[0198] The safety endpoints were:
[0199] • Occurrence of adverse events (AEs) / serious adverse events (including AEs suggestive of human abuse potential, abnormalities of physical examination, vital signs, electrocardiogram test and laboratory tests).
[0200] • Occurrence of protocol-specified adverse events of special interest.
[0201] • Suicidality as assessed by Columbia Suicide Severity Rating Scale (C-SSRS).
[0202] Statistical methods
[0203] The analyses for proof of concept (PoC) and dose-finding was performed using multiple comparison and modelling (M CP Mod) techniques. MCPMod was used to evaluate several possible dose response models (patterns) and to identify the best-fitting model or subset of models based on the Compound 1 and placebo treatment groups while protecting overall probability of Type I error, using a one-sided nominal a level of 10%. As a basis for the MCPMod, a mixed model repeated measures model (MM RM) was used, which is valid under the missing at random (MAR) assumption. The adjusted estimates from the MMRM were then extracted for use in the MCPMod analysis.
[0204] Two analysis sets were used. The treated set (TS) consisted of all patients who were randomised and treated with at least one dose of study drug; this set was used for the analysis of safety results. The full analysis set (FAS) consisted of all randomisation patients who were treated with at least one dose of study drug and had a baseline and at least one post-baseline on-treatment efficacy (ZAN-BPD) measurement. The FAS was used for the primary analysis.
[0205] Secondary efficacy parameters were analysed by a MMRM model similar to that of the primary efficacy endpoint. Descriptive statistics were used for safety parameters.
[0206] Results
[0207] The primary efficacy results of this trial are shown in Table 5, which details the change from baseline in the ZAN-BPD score during the 12 weeks of treatment in BPD patients receiving either placebo or one of 4 doses of Compound 1 (5mg, 25mg, 75mg or 125mg). The results of the phase II clinical trial show that, on average, all trial participants show a reduction in ZAN-BPD total score over the 12 weeks of treatment. The mean ZAN-BPD score decreases from a baseline of 16.2 + / - 5.1 (scores between 10-18 are considered moderate, and scores between 19-27 are considered serious) to an average of 7.2 + / - 5.5 at the end of the study (scores of 0-9 are considered mild).
[0208] Table 5 Change from baseline in ZAN-BPD in patients with BPD, by treatment group Table 6 shows safety data from the phase II clinical trial of patients with BPD, showing that during the 12 weeks of treatment Compound 1 does not increase the incidence of suicidal ideation nor non- suicidal self-injury as measured by the Columbia Suicide Severity Rating Scale (C-SSRS). Given the high prevalence of suicidal thinking and non-suicidal self-injury in patients with BPD, and the association of some psychiatric medications with increased risk for these behaviors (e.g., the Black Box warning for suicidality for selective serotonin reuptake inhibitors in children and adolescents), it is important to note that Compound 1 does not increase these behaviors.
[0209] Table 6 Assessment of suicidal ideation, suicidal behavior, and non-suicidal self-injury in patients with BPD at anytime during 12 weeks of treatment, by treatment group REFERENCES
[0210] Aviram R, Brodsky B, Stanley B. et.al Borderline Personality Disorder, Stigma, and Treatment Implications. Harv Rev Psychiatry 2006:1-8
[0211] Choi-Kain L, Finch E, Masland S. et.al What Works in the Treatment of Borderline Personality Disorder. Current Behavioral Neuroscience Reports 2017; Volume 4:1-10
[0212] Ellison W, Rosenstein L, Chelminski I. et.al The Clinical Significance of single features of Borderline Personality Disorder: Anger, Affective Instability, Impulsivity, and Chronic Emptiness in Psychiatric Outpatients. Journal of Personality Disorders, 29, 2015, 193 2016;Volume30:2:l-10
[0213] Ellison W, Rosenstein L, Morgan T. et.al Community and Clinical Epidemiology of Borderline Personality Disorder. Psychiatric Clinics of North America 2018; Volume 41:1-13
[0214] Kealy D, Ogrodniczuk J. et.al Marginalization of Borderline Personality Disorder. Journal of Psychiatric Practice 2010; Volume 16 (Issue 3):l-10
[0215] Klein P, Fairweather A, Lawn S. et.al Structural stigma and its impact on healthcare for borderline personality disorder: a scoping review. International Journal of Mental Health Systems 2022; Volume 48:1-41
[0216] Lieb K, Vollm B, Rucker G. et.al Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 2010: 1-12
[0217] Morgan, T. A., & Zimmerman, M. (2015). Is borderline personality disorder underdiagnosed and bipolar disorder overdiagnosed? In L. W. Choi-Kain & J. G. Gunderson (Eds.), Borderline personality and mood disorders: Comorbidity and controversy (pp. 65-78). Springer Science + Business Media, https: / / doi.org / 10.1007 / 978-l-4939-1314-5_4
[0218] Oldham J, Gabbard G, Goin M. et.al Practice Guideline for the Treatment of Patients With Borderline Personality Disorder 2010:1-82
[0219] Palihawadana V, Broadbear J, Rao S. et.al Reviewing the clinical significance of 'fear of abandonment' in borderline personality disorder Australasian Psychiatry 2019; Volume 27:1-4
[0220] Paris J. et.al Making psychotherapy for borderline personality disorder accessible. Annals of Clinical Psychiatry 2015; Volume 27:4: 1-5
[0221] Shah R, Zanarini M. et.al Comorbidity of Borderline Personality Disorder Current Status and Future Directions 2018;41:1-11
[0222] Skodol A, Siever L, Livesley W. et.al The Borderline Diagnosis II: Biology, Genetics, and Clinical Course. 2002; Volume 51:12:1-13
[0223] Temes C, Zanarini M. et.al The Longitudinal Course of Borderline Personality Disorder. Psychiatric Clinics of North America 2018: Volume 41:1-10
Claims
CLAIMS[1] 7-(4-chlorobenzyl)-l-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7- dihydro-lH-purine-2, 6-dione (Compound 1) for use in the prevention or treatment of Borderline Personality Disorder (BPD).[2] Pharmaceutical composition comprising Compound 1 for use in the prevention or treatment of BPD.[3] Compound 1 or pharmaceutical composition comprising Compound 1 for use according to claim 1 or claim 1, wherein the prevention or treatment of BPD is in adults.[4] Compound 1 or pharmaceutical composition comprising Compound 1 for use according to any of claims 1 to 3, wherein the use is in the treatment of BPD.[5] Compound 1 or pharmaceutical composition comprising Compound 1 for use according to any of claims 1 to 4, wherein Compound 1 is administered in an amount of 50 mg to 150 mg, preferably in amount of 75 mg to 125 mg, and more preferably in an amount of 75 or 125 mg per day.[6] Compound 1 or pharmaceutical composition comprising Compound 1 for use according to any of claims 1 to 5, wherein the patient suffering from BPD exhibits at the beginning of the treatment a Zanarini Borderline Personality Disorder (ZAN-BPD) score of > 9, with a question #2 Affective Instability score of >2.[7] Compound 1 or pharmaceutical composition comprising Compound 1 for use according to any of claims 1 to 6, wherein the treatment does not increase the incidence of suicidal ideation or non-suicidal self-injury as measured by the Columbia Suicide Severity Rating Scale (C-SSRS).
Citation Information
Patent Citations
Substituted xanthine derivatives
WO2020120449A1
EP22214917A
EP23155058A
